SEC Comment Letter 0000000000-23-000043 to AIxCrypto Holdings, Inc. (AIXC)

AIxCrypto Holdings, Inc.
Date: Jan. 3, 2023 · CIK: 0001460702 · Accession: 0000000000-23-000043

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-269088

Date

January 3, 2023

Author

Michael S. Poirier

Form

UPLOAD

Company

AIxCrypto Holdings, Inc.

Letter

United States securities and exchange commission logo January 3, 2023 Michael S. Poirier Chief Executive Officer Qualigen Therapeutics, Inc. 2042 Corte Del Nogal Carlsbad, California 92011 Re:Qualigen Therapeutics, Inc. Registration Statement on Form S-3 Filed December 30, 2022 File No. 333-269088 Dear Michael S. Poirier: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Wendy Grasso

Show Raw Text

United States securities and exchange commission logo
January 3, 2023
Michael S. Poirier
Chief Executive Officer
Qualigen Therapeutics, Inc.
2042 Corte Del Nogal
Carlsbad, California 92011
Re:Qualigen Therapeutics, Inc.
Registration Statement on Form S-3
Filed December 30, 2022
File No. 333-269088
Dear Michael S. Poirier:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Wendy Grasso

SecProbe.io